Norethindrone: Nursing Drug Guide, Thrombotic Risk & Hold Rules
Healthcare medication guide: thrombotic and VTE risk screening before progestin therapy, contraindication checks, POP 3-hour missed-dose backup rules, and hold criteria for norethindrone 0.35 mg and norethindrone acetate 5 mg regimens.
Progestin therapy—including norethindrone POP and norethindrone acetate—can increase thrombotic and thromboembolic risk. Hold and clarify before the first dose when history suggests active or recent deep vein thrombosis, pulmonary embolism, or stroke, undiagnosed vaginal bleeding, breast cancer, or liver disease. For Camila 0.35 mg POP, a dose taken more than 3 hours late requires backup contraception for 48 hours. Screen smoking status, hypertension, diabetes, obesity, migraine with aura, and prolonged immobilization—then monitor for leg swelling, chest pain, dyspnea, and neurovascular symptoms throughout therapy.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, calculate the patient’s total norethindrone in the last 24 hours from every route and every combination product—not just the order in front of you. Exceeding the maximum daily limit can cause irreversible hepatic injury even when each individual dose looks appropriate.
Most common brand names
Norethindrone appears as a progestin-only contraceptive (POP) and as norethindrone acetate for non-contraceptive progestin therapy. Verify formulation and indication on every order—dosing, timing, and counseling differ.
Contraceptive (0.35 mg): Camila (norethindrone tablets USP 0.35 mg) and other POP / minipill products. Therapeutic (5 mg acetate): Norethindrone Acetate Tablets USP, 5 mg (Mylan and generics). Norethindrone acetate is rapidly deacetylated to norethindrone after oral administration.
Why we give it — Indications
Nurses encounter norethindrone in family planning clinics, postpartum units, gynecology, and outpatient endocrine care. Match monitoring and teaching to whether the patient is on continuous contraception or a therapeutic progestin course.
| Formulation | Indications (labeling) |
|---|---|
| Norethindrone 0.35 mg POP (Camila) | Prevention of pregnancy (progestin-only oral contraceptive). Typical first-year failure rate about 5% with usual use; about 0.5% with perfect use per labeling. |
| Norethindrone acetate 5 mg | Secondary amenorrhea; endometriosis; abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology (e.g., not for known submucous fibroids or uterine cancer). Not indicated for concomitant estrogen in postmenopausal women for endometrial protection. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
POP (0.35 mg): Camila labeling describes contraceptive action through suppressing ovulation in approximately half of users, thickening cervical mucus, lowering mid-cycle LH/FSH peaks, slowing ovum transport, and altering the endometrium.
Norethindrone acetate (5 mg): Induces secretory changes in an estrogen-primed endometrium; on a weight basis it is twice as potent as norethindrone. After oral dosing, norethindrone acetate is completely and rapidly deacetylated to norethindrone.
Progestin therapy may alter coagulation parameters and lipid/carbohydrate metabolism per norethindrone acetate labeling—relevant when assessing patients with vascular risk factors or diabetes.
Dosing overview
Always confirm which product is ordered. POP failure risk rises sharply with late or missed pills; therapeutic acetate uses indication-specific courses.
Missed dose (POP): If more than 3 hours late or one or more pills missed: take the missed pill as soon as remembered, return to the regular schedule, and use backup contraception (e.g., condoms and spermicides) for every episode of sex for the next 48 hours per Camila patient labeling.
Vomiting/diarrhea (POP): Use backup method for 48 hours if vomiting soon after a dose per patient labeling.
Onset, peak, duration, and half-life
| Parameter | Camila 0.35 mg | Norethindrone acetate 5 mg | Nursing relevance |
|---|---|---|---|
| Absorption / Tmax | Rapid; mean Tmax ~1.2 h (range 0.5–2 h) | Rapid; NET Tmax ~1.83 h (SD 0.58) | POP timing window is narrow—late doses reduce efficacy |
| Peak concentration | Mean Cmax ~4817 pg/mL (single dose) | Mean Cmax ~26.19 ng/mL NET | Do not equate POP and acetate potency by tablet strength alone |
| Half-life | Mean terminal t½ ~7.7 h (single dose) | Mean terminal t½ ~8.51 h NET | Missed POP doses matter same day—not “catch up tomorrow” |
| Bioavailability | ~65% absolute (first-pass metabolism) | Deacetylated to NET; disposition same as oral NET | GI illness may reduce absorption—backup contraception per POP labeling |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm indication: contraceptive POP vs therapeutic norethindrone acetate—and correct tablet strength (0.35 mg vs 5 mg)
- Screen thrombotic history: active or recent DVT, PE, stroke, or arterial thromboembolism (contraindicated for norethindrone acetate per labeling)
- Pregnancy test or rule out pregnancy before initiation; hold if pregnant (Category X for norethindrone acetate)
- Review undiagnosed vaginal bleeding, breast cancer history, liver disease/tumors, smoking, hypertension, diabetes, migraine pattern, and immobilization
- Perform medication reconciliation for enzyme inducers (rifampin, some anticonvulsants, St. John’s wort) that may reduce POP efficacy
Contraindications
- POP (Camila): Known or suspected pregnancy; known or suspected breast cancer; undiagnosed abnormal genital bleeding; hypersensitivity; benign or malignant liver tumors; acute liver disease
- Norethindrone acetate 5 mg: Pregnancy; undiagnosed vaginal bleeding; known/suspected/history of breast cancer; active DVT, PE, or history; active/recent arterial thromboembolism; impaired liver function or liver disease; hypersensitivity
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Enzyme inducers (rifampin, phenytoin, carbamazepine, barbiturates, etc.) | May reduce contraceptive steroid levels; unintended pregnancy or breakthrough bleeding (POP labeling) | Counsel on backup methods; notify prescriber for alternative contraception review |
| St. John’s wort | May reduce effectiveness of contraceptive steroids (POP labeling) | Document herbal use; advise backup contraception and prescriber follow-up |
| Anti-HIV protease inhibitors | May alter estrogen/progestin levels when combined products used; consult individual labels (POP section) | Coordinate with pharmacy; reinforce adherence and bleeding surveillance |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet only for the products reviewed.
- Administer at the same time daily for POP; continuous dosing with no gap between packs
- Teach patients to start the next pack the day after finishing the last pack (POP)
- For therapeutic acetate, follow prescriber course length (e.g., 5–10 days for withdrawal bleed induction or titrated endometriosis regimen)
- Follow medication administration rights; document formulation strength and indication on the MAR
Camila patient labeling: if a POP is more than 3 hours late or missed, take the pill as soon as remembered, resume the usual time, and use backup contraception for 48 hours with every sexual encounter. This is a primary nursing safety teaching point for contraceptive failure prevention.
Expected therapeutic response
- Contraceptive: Prevention of pregnancy when taken on time; counsel that POPs do not protect against HIV or other STDs per labeling
- Amenorrhea / abnormal bleeding: Progestin withdrawal bleeding typically within 3–7 days after a short acetate course per labeling
- Endometriosis: Reduced pain/bleeding over months; breakthrough bleeding may occur during dose titration—document and notify prescriber
- Irregular spotting is common on POPs and does not always mean failure—distinguish expected bleeding pattern from thrombotic or pregnancy red flags
Red flags — Stop and act
Norethindrone acetate patient labeling lists thrombotic warning signs. Hold the dose and escalate per facility protocol when these appear.
- Chest pain, shortness of breath, or calf/leg pain suggesting DVT or PE
- Sudden severe headache, changes in speech, dizziness, or vision changes (partial/complete loss, diplopia)—discontinue and evaluate per labeling
- Suspected pregnancy—stop POP/acetate and notify prescriber; evaluate for ectopic pregnancy if abdominal pain on POP (labeling)
- Acute severe abdominal pain on POP—possible ectopic pregnancy or ovarian cyst—urgent assessment
- Jaundice, severe RUQ pain, or abnormal liver function tests suggesting hepatic injury
- New breast lump, severe depression recurrence, or anaphylactic symptoms
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Irregular menstrual bleeding / spotting | Most common POP side effect (labeling) | Teach expected pattern; rule out pregnancy and nonadherence if pattern changes |
| Headache, breast tenderness, nausea, dizziness | Increased among some POP users (labeling) | Assess severity; discontinue if migraine pattern worsens per POP precautions |
| Edema, weight change | Listed for progestins (acetate labeling) | Track blood pressure, weight, and fluid status; notify if rapid gain with dyspnea |
| Thrombotic / thromboembolic events | Serious—DVT, PE, stroke, retinal thrombosis (acetate labeling) | Hold drug; emergency pathway; do not restart without specialist clearance |
| Hepatic effects | Cholestatic jaundice; LFT abnormalities (acetate labeling) | Hold; obtain LFTs; contraindicated in marked hepatic impairment |
| Mood changes / depression | Clinical depression may worsen (acetate precautions) | Screen mood; discontinue if serious recurrence per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Overdose and toxicity
Camila overdosage labeling: no reports of serious ill effects from overdose, including ingestion by children. Supportive care and monitoring still apply—verify number of tablets taken and contact prescriber/poison control or toxicology services per facility protocol.
Therapeutic mis-dosing (wrong strength or duplicate progestin) is a more common inpatient risk than acute toxicity. Clarify 0.35 mg vs 5 mg on the MAR and educate patients not to double doses.
Look-alike / sound-alike and error prevention
- Norethindrone vs norethindrone acetate—different indications and strengths (0.35 mg POP vs 5 mg therapeutic)
- Norethindrone vs medroxyprogesterone / other progestins—verify generic name on order and label
- Camila POP vs combined oral contraceptives—POP lacks estrogen; different missed-pill rules than combined pills
- Ethinyl estradiol/norethindrone combinations—do not confuse with progestin-only or acetate tablets
- Spell out progestin-only on MAR comments when applicable; independent double-check for reproductive-age patients with VTE history
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Same-time dosing | Set a daily alarm for POP; document exact administration time on the MAR when feasible. |
| Late dose script | >3 h late = missed for POP purposes → backup 48 h (condoms/spermicide per labeling). |
| Vomiting/diarrhea | POP: backup contraception 48 h after vomiting soon after a dose. |
| Storage | 20–25°C (68–77°F) per both labels; protect from moisture. |
| Labs | No routine lab for POP; obtain LFTs if hepatic symptoms; pregnancy test when indicated. |
| Commonly missed | Switching from combined pills without teaching new timing rules; enzyme-inducing antibiotics. |
| Ask pharmacy when | Drug interactions, formulation substitution, or unclear amenorrhea/endometriosis course. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| History of VTE / stroke / arterial disease | Active or recent thromboembolism is contraindicated for norethindrone acetate; manage cardiovascular risk factors per labeling (hypertension, diabetes, smoking, obesity, SLE). |
| Smokers | Camila labeling advises women using oral contraceptives not to smoke; assess tobacco use at admission and counsel per protocol. |
| Breast cancer / undiagnosed bleeding | Contraindicated or requires specialist clearance; rule out nonfunctional causes of bleeding before continuing therapy. |
| Liver disease | Acute liver disease and hepatic tumors contraindicated; monitor for jaundice and LFT changes. |
| Diabetes / hyperlipidemia | Prediabetic and diabetic women on POPs should be monitored (Camila); lipid and glucose effects possible with progestin therapy (acetate). |
| Pregnancy / postpartum / lactation | Pregnancy Category X for acetate—do not use in pregnancy. POPs: rule out pregnancy before start; small amounts in breast milk; isolated decreased milk production reported—monitor infants for jaundice per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure, weight, edema, and thrombotic symptoms (leg pain, chest pain, dyspnea, neuro symptoms)
- Menstrual pattern, breakthrough bleeding, amenorrhea, and pregnancy possibility
- Mood, headache pattern, and vision changes
- Hepatic symptoms and LFTs when clinically indicated
- Adherence time stamps for POP—document late doses and backup counseling provided
Document
- Formulation (0.35 mg POP vs 5 mg acetate), indication, dose, time, and patient teaching on 3-hour/48-hour rules
- Contraindication screen completed (VTE, pregnancy, liver disease, breast cancer, bleeding)
- Backup contraception education when doses late or interacting drugs present
Patient teaching
- Take POP at the same time every day; if more than 3 hours late, take the pill immediately and use backup birth control for 48 hours with every sexual encounter
- POPs do not prevent HIV or other sexually transmitted infections—barrier protection when at risk
- Report chest pain, leg pain, sudden severe headache, vision changes, abdominal pain, breast lumps, or yellowing skin immediately
- Irregular bleeding may occur—do not stop the POP without prescriber advice unless red-flag symptoms develop
- Tell all clinicians you are on progestin therapy before starting new medicines (especially seizure drugs, TB therapy, or herbals)
- For norethindrone acetate courses, explain expected withdrawal bleeding after short courses and when to call for heavy or prolonged bleeding (menorrhagia evaluation)
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Suspected or confirmed pregnancy
- Active DVT, PE, stroke, or other acute thrombotic event; or contraindicated vascular history for acetate
- Undiagnosed abnormal vaginal bleeding until evaluated
- Known or suspected breast cancer, acute liver disease, or hepatic tumors
- New thrombotic warning signs (chest pain, dyspnea, unilateral leg swelling, sudden neuro/vision changes)
- Wrong product/strength ordered (0.35 mg POP vs 5 mg acetate) or duplicate progestin without prescriber intent
- Hypersensitivity or anaphylaxis after prior dose
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Progestin safety is not only about the tablet—it is about who should not receive it and how strictly POP timing is kept. Build VTE screening and late-dose counseling into admission and discharge workflows for reproductive-age patients.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right formulation (0.35 mg vs 5 mg acetate)
- Thrombotic contraindication screen documented on first inpatient dose
- For POP: confirm last dose time; if >3 hours late, trigger backup-contraception teaching before documenting administration
- Pregnancy possibility assessed when amenorrhea, missed pills, or abdominal pain present
2. High-alert and safety badge
Not a universal high-alert medication, but thrombotic risk requires heightened surveillanceTreat initiation like hormone therapy with vascular risk: align with pharmacy on interactions and with prescribers on hold criteria when VTE symptoms emerge.
3. Clinical workflow: hold and question rules
- Hold any dose when active VTE symptoms appear—do not wait for imaging results to escalate nursing concerns
- Clarify orders that say “norethindrone” without strength when both POP and acetate exist on formulary
- Postpartum/breastfeeding patients: confirm labeling-appropriate start time and milk-supply monitoring
4. Critical teach-back questions
- “What will you do if your POP is more than 3 hours late?” (Take pill now, resume schedule, backup method 48 hours for all sex.)
- “Which symptoms mean you should seek care immediately?” (Chest pain, leg pain, sudden severe headache, vision changes, severe abdominal pain.)
5. Care coordination
Pharmacist: Formulation verification, enzyme-inducer interactions, and therapeutic course clarification for acetate
Prescriber / OB-GYN: Breakthrough bleeding, pregnancy suspicion, contraindication review, and transition between contraceptive methods
🧠 Quick mental checklist
- Is this 0.35 mg POP or 5 mg norethindrone acetate—and does the indication match?
- Any history of DVT, PE, stroke, breast cancer, liver disease, or unexplained bleeding?
- For POP: was the last dose within 3 hours—and was backup counseling done if late?
- Any chest pain, leg swelling, sudden headache, or vision change today?
- Could this patient be pregnant?
Norethindrone NCLEX practice questions
Practice NCLEX-style clinical judgment practice for norethindrone using a tabbed case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), trend interpretation, documentation cloze, ordered steps, and matrix urgency—screen thrombotic risk → verify contraindications → teach POP timing → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Camila (norethindrone) 0.35 mg PO daily — scheduled 2100; last given yesterday 2145
- Today 0030: patient reports forgot 2100 dose; offered tablet now
- Rifampin 600 mg PO daily (TB therapy) started this admission — 0800 dose given
- Norethindrone 650 mg PO q6h PRN — not given
- Admission: hCG negative; BMP WNL; AST 24 U/L, ALT 22 U/L
- 1200: repeat hCG ordered for amenorrhea concern — pending
- No coagulation studies yet
- 24-year-old postpartum day 5, breastfeeding, on POP for contraception
- History: superficial DVT age 19 treated 6 months anticoagulation, resolved
- Smokes 5 cigarettes/day; BMI 31
- New diagnosis latent TB — rifampin initiated today
- 0030: Alert; no chest pain; calves soft, equal; lungs clear
- 0035: Patient asks if “missing by a few hours still counts as on time” for POP
- 0040: Prior shift documented contraceptive counseling not yet repeated after rifampin start
Answer key & rationale
Frequently asked questions
When should a nurse hold norethindrone and notify the prescriber?
Hold and notify for suspected or confirmed pregnancy, active or recent arterial thromboembolism, active DVT or PE, known or suspected breast cancer, undiagnosed abnormal vaginal bleeding, acute liver disease or hepatic tumors, hypersensitivity, or new thrombotic warning signs (chest pain, leg pain, sudden severe headache, vision changes) per labeling.
What should nurses teach about a late progestin-only pill (POP)?
Camila patient labeling: if a POP is more than 3 hours late or missed, take the missed pill as soon as remembered, resume the regular time, and use backup contraception for every episode of sex during the next 48 hours.
Does norethindrone acetate 5 mg work the same as Camila 0.35 mg?
No. Camila is continuous contraception with strict daily timing. Norethindrone acetate 5 mg is therapeutic progestin for amenorrhea, abnormal uterine bleeding, or endometriosis with course-specific dosing (e.g., 2.5–10 mg daily for 5–10 days, or titration to 15 mg for endometriosis).
What thrombotic signs require immediate escalation?
Norethindrone acetate patient information lists chest pain, shortness of breath, severe headaches, leg pain, speech changes, dizziness, and vision changes. Hold the dose and escalate per facility protocol.
Can breastfeeding patients use norethindrone POP?
Small amounts of progestin pass into breast milk per Camila labeling; isolated decreased milk production has been reported. Follow labeling start times after delivery and monitor feeding; counsel on backup methods when doses are late.
References
-
U.S. National Library of Medicine. CAMILA (norethindrone) tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a786be85-49ba-4369-b510-7dccc10f7f18
-
U.S. National Library of Medicine. NORETHINDRONE ACETATE tablets USP, 5 mg — Full prescribing information. DailyMed (Mylan Pharmaceuticals Inc.).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e8e531a-dac2-44ce-b06b-390296c26833
-
Drugs and Lactation Database (LactMed). Norethindrone. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501291/
-
Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use.https://www.cdc.gov/contraception/hcp/usmec/index.html
-
Centers for Disease Control and Prevention. U.S. Selected Practice Recommendations for Contraceptive Use.https://www.cdc.gov/contraception/hcp/us-spr/index.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.